221 related articles for article (PubMed ID: 32894113)
1. Inhibiting MAPK14 showed anti-prolactinoma effect.
Ding QY; Zhang Y; Ma L; Chen YG; Wu JH; Zhang HF; Wang X
BMC Endocr Disord; 2020 Sep; 20(1):138. PubMed ID: 32894113
[TBL] [Abstract][Full Text] [Related]
2. The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas.
Wang S; Wang A; Zhang Y; Zhu K; Wang X; Chen Y; Wu J
BMC Endocr Disord; 2021 Nov; 21(1):235. PubMed ID: 34814904
[TBL] [Abstract][Full Text] [Related]
3. TLR4 inhibition suppresses growth in oestrogen-induced prolactinoma models.
Zhang Y; Ma L; Dong S; Ding Q; Wang S; Wu Q; Ni P; Zhang H; Chen Y; Wu J; Wang X
Endocr Relat Cancer; 2022 Dec; 29(12):703-716. PubMed ID: 36219868
[TBL] [Abstract][Full Text] [Related]
4. Laminin inhibits lactotroph proliferation and is reduced in early prolactinoma development.
Kuchenbauer F; Theodoropoulou M; Hopfner U; Stalla J; Renner U; Tonn JC; Low MJ; Arzt E; Stalla GK; Páez-Pereda M
Mol Cell Endocrinol; 2003 Sep; 207(1-2):13-20. PubMed ID: 12972179
[TBL] [Abstract][Full Text] [Related]
5. PBK/TOPK Inhibitor Suppresses the Progression of Prolactinomas.
Zhu K; Cheng X; Wang S; Zhang H; Zhang Y; Wang X; Chen Y; Wu J
Front Endocrinol (Lausanne); 2021; 12():706909. PubMed ID: 35126305
[TBL] [Abstract][Full Text] [Related]
6. [Melatonin inhibits the proliferation of pituitary prolactin-secreting tumor by suppressing the enhancer elements mutation of PRL gene in the rat].
Gao L; Yang QH; Xu RK
Sheng Li Xue Bao; 2005 Jun; 57(3):319-27. PubMed ID: 15968426
[TBL] [Abstract][Full Text] [Related]
7. HER2/ErbB2 receptor signaling in rat and human prolactinoma cells: strategy for targeted prolactinoma therapy.
Fukuoka H; Cooper O; Mizutani J; Tong Y; Ren SG; Bannykh S; Melmed S
Mol Endocrinol; 2011 Jan; 25(1):92-103. PubMed ID: 21106881
[TBL] [Abstract][Full Text] [Related]
8. The Balance of PI3K and ERK Signaling Is Dysregulated in Prolactinoma and Modulated by Dopamine.
Roof AK; Jirawatnotai S; Trudeau T; Kuzyk C; Wierman ME; Kiyokawa H; Gutierrez-Hartmann A
Endocrinology; 2018 Jun; 159(6):2421-2434. PubMed ID: 29726995
[TBL] [Abstract][Full Text] [Related]
9. Ovarian dependence for pituitary tumorigenesis in D2 dopamine receptor-deficient mice.
Hentges ST; Low MJ
Endocrinology; 2002 Dec; 143(12):4536-43. PubMed ID: 12446580
[TBL] [Abstract][Full Text] [Related]
10. Tumor stem-like cells isolated from MMQ cells resist to dopamine agonist treatment.
Cai L; Chen J; Lu J; Li Q; Chen X; Zhang L; Wu J; Zheng W; Wang C; Su Z
Mol Cell Endocrinol; 2021 Sep; 535():111396. PubMed ID: 34271069
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effects of antivascular endothelial growth factor strategies in experimental dopamine-resistant prolactinomas.
Luque GM; Perez-Millán MI; Ornstein AM; Cristina C; Becu-Villalobos D
J Pharmacol Exp Ther; 2011 Jun; 337(3):766-74. PubMed ID: 21406548
[TBL] [Abstract][Full Text] [Related]
12. Either isoform of the dopamine D2 receptor can mediate dopaminergic repression of the rat prolactin promoter.
McChesney R; Sealfon SC; Tsutsumi M; Dong KW; Roberts JL; Bancroft C
Mol Cell Endocrinol; 1991 Aug; 79(1-3):R1-7. PubMed ID: 1834494
[TBL] [Abstract][Full Text] [Related]
13. mPRs represent a novel target for PRL inhibition in experimental prolactinomas.
Camilletti MA; Abeledo-Machado A; Perez PA; Faraoni EY; De Fino F; Rulli SB; Ferraris J; Pisera D; Gutierrez S; Thomas P; Díaz-Torga G
Endocr Relat Cancer; 2019 May; 26(5):497-510. PubMed ID: 30856609
[TBL] [Abstract][Full Text] [Related]
14. Endogenous expression of Neuregulin-1 (Nrg1) as a potential modulator of prolactin (PRL) secretion in GH3 cells.
Zhao W; Shen Y; Ren S
Cell Tissue Res; 2011 May; 344(2):313-20. PubMed ID: 21437657
[TBL] [Abstract][Full Text] [Related]
15. Does DRD2 polymorphism influence the clinical characteristics of prolactinoma?
Ilhan M; Kahraman OT; Turan S; Turgut S; Karaman O; Zeybek U; Shukurov S; Yaylim I; Tasan E
Ann Endocrinol (Paris); 2015 Oct; 76(5):614-9. PubMed ID: 26514951
[TBL] [Abstract][Full Text] [Related]
16. Heregulin regulates prolactinoma gene expression.
Vlotides G; Cooper O; Chen YH; Ren SG; Greenman Y; Melmed S
Cancer Res; 2009 May; 69(10):4209-16. PubMed ID: 19401448
[TBL] [Abstract][Full Text] [Related]
17. Resistance to dopamine agonists in prolactinoma is correlated with reduction of dopamine D2 receptor long isoform mRNA levels.
Shimazu S; Shimatsu A; Yamada S; Inoshita N; Nagamura Y; Usui T; Tsukada T
Eur J Endocrinol; 2012 Mar; 166(3):383-90. PubMed ID: 22127489
[TBL] [Abstract][Full Text] [Related]
18. Lack of prolactin receptor signaling in mice results in lactotroph proliferation and prolactinomas by dopamine-dependent and -independent mechanisms.
Schuff KG; Hentges ST; Kelly MA; Binart N; Kelly PA; Iuvone PM; Asa SL; Low MJ
J Clin Invest; 2002 Oct; 110(7):973-81. PubMed ID: 12370275
[TBL] [Abstract][Full Text] [Related]
19. CEBPD suppresses prolactin expression and prolactinoma cell proliferation.
Tong Y; Zhou J; Mizutani J; Fukuoka H; Ren SG; Gutierrez-Hartmann A; Koeffler HP; Melmed S
Mol Endocrinol; 2011 Nov; 25(11):1880-91. PubMed ID: 21980073
[TBL] [Abstract][Full Text] [Related]
20. Leukemia inhibitory factor regulates prolactin secretion in prolactinoma and lactotroph cells.
Ben-Shlomo A; Miklovsky I; Ren SG; Yong WH; Heaney AP; Culler MD; Melmed S
J Clin Endocrinol Metab; 2003 Feb; 88(2):858-63. PubMed ID: 12574225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]